Abstract:Clinical Trials, Ahead of Print. Background:Clinical trials are increasingly using Bayesian methods for their design and analysis. Inference in Bayesian trials typically uses simulation-based approaches such as Markov Chain Monte Carlo methods. Markov Chain Monte Carlo has high computational cost and can be complex to implement. The Integrated Nested Laplace Approximations algorithm provides approximate Bayesian inference without the need for computationally complex simulations, making it more efficient than Markov Chain Monte Carlo. The practical properties of Integrated Nested Laplace Approximations compared to Markov Chain Monte Carlo have not been considered for clinical trials. Using data from a published clinical trial, we aim to investigate whether Integrated Nested Laplace Approximations is a feasible and accurate alternative to Markov Chain Monte Carlo and provide practical guidance for trialists interested in Bayesian trial design.Methods:Data from an international Bayesian multi-platform adaptive trial that compared therapeutic-dose anticoagulation with heparin to usual care in non-critically ill patients hospitalized for COVID-19 were used to fit Bayesian hierarchical generalized mixed models. Integrated Nested Laplace Approximations was compared to two Markov Chain Monte Carlo algorithms, implemented in the software JAGS and stan, using packages available in the statistical software R. Seven outcomes were analysed: organ-support free days (an ordinal outcome), five binary outcomes related to survival and length of hospital stay, and a time-to-event outcome. The posterior distributions for the treatment and sex effects and the variances for the hierarchical effects of age, site and time period were obtained. We summarized these posteriors by calculating the mean, standard deviations and the 95% equitailed credible intervals and presenting the results graphically. The computation time for each algorithm was recorded.Results:The average overlap of the 95% credible interval for the treatment and sex effects estimated using Integrated Nested Laplace Approximations was 96% and 97.6% compared with stan, respectively. The graphical posterior densities for these effects overlapped for all three algorithms. The posterior mean for the variance of the hierarchical effects of age, site and time estimated using Integrated Nested Laplace Approximations are within the 95% credible interval estimated using Markov Chain Monte Carlo but the average overlap of the credible interval is lower, 77%, 85.6% and 91.3%, respectively, for Integrated Nested Laplace Approximations compared to stan. Integrated Nested Laplace Approximations and stan were easily implemented in clear, well-established packages in R, while JAGS required the direct specification of the model. Integrated Nested Laplace Approximations was between 85 and 269 times faster than stan and 26 and 1852 times faster than JAGS.Conclusion:Integrated Nested Laplace Approximations could reduce the computational complexity of Bayesian analysis in clinical trials as it is easy to implement in R, substantially faster than Markov Chain Monte Carlo methods implemented in JAGS and stan, and provides near identical approximations to the posterior distributions for the treatment effect. Integrated Nested Laplace Approximations was less accurate when estimating the posterior distribution for the variance of hierarchical effects, particularly for the proportional odds model, and future work should determine if the Integrated Nested Laplace Approximations algorithm can be adjusted to improve this estimation.

An evaluation of confidence intervals for a cumulative proportion to enable decisions at interim reviews of single-arm trials

Covariate-adjusted Group Sequential Comparisons of Survival Probabilities

Comparison of baseline covariate adjustment methods for restricted mean survival time

Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power

Repeated Confidence Intervals and Prediction Intervals Using Stochastic Curtailment under Fractional Brownian Motion

Sample size re-estimation in crossover trials: application to the AIM HY-INFORM study

Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure

Confidence intervals for overall response rate difference in the sequential parallel comparison design

Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting

Two-sided confidence interval of a binomial proportion: how to choose?

Confidence Intervals for Ratios of Proportions in Stratified Bilateral Correlated Data

A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study

Intent-to-treat Analysis of Cluster Randomized Trials when Clusters Report Unidentifiable Outcome Proportions.

Prognostic Covariate Adjustment for Binary Outcomes Using Stratification

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

A comparison of computational algorithms for the Bayesian analysis of clinical trials

Interval estimation of relative risks for combined unilateral and bilateral correlated data

Changing interim monitoring in response to internal clinical trial data

Primary analysis method for incomplete CD4 count data from IMPI trial and other trials with similar setting

Cost-Efficient Fixed-Width Confidence Intervals for the Difference of Two Bernoulli Proportions

Conditional Power and Friends: The Why and How of (Un)planned, Unblinded Sample Size Recalculations in Confirmatory Trials